Work

76P Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: To continue or not to continue?

Year: 2024

Type: article

Abstract: Background: Adebrelimab is a novel humanised IgG4 monoclonal antibody against PD-L1, indicated for the first-line treatment of adult Patients with ES-SCLC in China.A registry study was conducted with the use of disease-specific database of lung cancer, at 21 Centres in Jiangsu, China.Here, we report results of Cohort ADBL-LC-001: the efficacy and safety of adebrelimab in the first-line treatment of patients with SCLC.Methods: We prospectively collected medical records from patients with SCLC, who initiated first-line treatment with adebrelimab.Primary endpoint is progression-free survival (PFS) by RECIST 1.1, secondary endpoints included overall survival (OS), objective response rate (ORR) , disease control rate (DCR) and safety.Results: Between March 2023 and March 2024, 143 patients were included, the median follow-up was 10.3 months.Overall, 114(80%) patients were ES-SCLC and 29(80%) LS-SCLC, median age was 67 years (rang, 34-84), and most patients were 65 years (62%), male (78%), with an ECOG score of one (90%).29 (25%) patients with ES-SCLC had liver metastases, 23 (20%) had Brain metastases.In the group ES-SCLC, mOS was 12.4 months (95% CI, 10.0-14.9)and mPFS was 6.7 months (95% CI, 5.3-7.7), the ORR, DCR was 34.2%, 85.1%, respectively.In the group LS-SCLC, mOS was 15.4 months (95% CI, 13.7-NA) and mPFS was 14.6 months (95% CI, 13.4-15.4),the ORR, DCR was 51.7%, 96.6%, respectively.In the IIT population, TEAEs occurred in 136 (95.1%) patients, grade 3 or worse TEAEs occurred in 29 (20.3%)patients.The most common grade 3 TEAEs were neutrophil count decreased (8.4%), lymphocyte count decreased (5.6%), anemia (3.5%), white blood cell decreased (2.8%), g-glutamyltransferase increased (2.8%).The safety profile was generally manageable, without any unexpected adverse events.Conclusions: This Real-world data verified the efficacy and safety of adebrelimab in the first-line treatment of patients with SCLC.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100819

Authors: M. Smith, M. Robinson, N. Cook, A. O'Reilly

Institutions: National Health Service, The Christie NHS Foundation Trust, University of Manchester

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170